Die Einträge von „Technologien aus Wien“ sind in der Projektsprache abgebildet.
Technologien aus Wien
APEPTICO Forschung und Entwicklung GmbH
Developing peptide-based products targeting chronic and life-threatening diseasesAPEPTICO is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening pulmonary diseases.
By concentrating on synthetically produced protein molecules, APEPTICO shiftes the paradigm of therapeutic proteins from cell-technology to chemical synthesis. Synthetically manufactured proteins avoid the general risks associated to gene-technologies, and are much faster to produce at significant lower cost.
Establishment of peptide drugs for the treatment of life-threatening pseudohypoaldosteronism type IBAutosomal recessive pseudohypoaldosteronism type I (PHA type 1B) is caused by homozygous or compound heterozygous loss-of-function mutations in any one of three genes encoding subunits of the epithelial sodium channel (ENaC): the alpha subunit, the beta subunit, the gamma subunit (SCNN1G).
About 50 mutations in ENaC, causing PHA type1B in the homozygous or compound heterozygous state have been characterised and reported.
Non-function of ENaC results in loss of sodium in the urine and faeces and severe salt imbalance in the body. Characteristic features are low levels of sodium (hyponatremia) and high levels of potassium (hyperkalemia) in the blood. Newborns fail to thrive and suffer from severe dehydration; other symptoms are abnormal heartbeat or shock due to salt imbalance. Patients with PHA type 1B frequently develop a childhood pulmonary syndrome.
PHA type 1B is a life-threatening condition which first presents in new-borns and young patients. Today, no satisfactory method exist for the treatment of PHA type 1B.
APEPTICO aims to develop a first-line first-in-its-class peptide drug-based medicine for treatment of patients suffering from PHA type 1B.
Kontakt Wirtschaftsagentur Wien
Die Informations- und Vernetzungsangebote werden im Rahmen des Projektes „IC3 Innovation by Co-Operation, Co-Creation and Community Building“ aus Mitteln des Europäischen Fonds für regionale Entwicklung kofinanziert. Nähere Informationen zum IWB/EFRE-Förderprogramm